NCT03560882进行中（未招募）1 期
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies
Joaquina Baranda2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2018年7月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Change in conformational mutant tumor protein 53 (p53)
研究概览
简要总结
This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability of participant to understand this study, and participant to sign a written informed consent. Legally authorized representative is not allowed to sign consent for participant.
- •Participants with tumor protein 53 (TP53) immunohistochemistry (IHC)-positive tumors
- •Participants whose screening IHC shows TP53-IHC-negative including wild type (WT) and null.
- •Participants with histologic or cytologic confirmation of any malignant disease who are planning and eligible to undergo surgical resection. For participants with Solid Tumors Only
- •Participants with previously treated acute myeloid leukemia (AML) are eligible if they relapse and are in between two treatment regimens
- •No concurrent or recent (within 30 days) use of systemic therapy including chemotherapy, immunotherapy, hormonal therapy, cancer vaccine, or local therapy for the cancer.
- •Formalin-fixed paraffin-embedded (FFPE) tumor tissue deemed adequate for IHC analysis and next generation sequencing (NGS) are required. Bone marrow aspirate tissue samples from participants with AML are required.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Adequate organ and marrow function
- •A negative urine or serum pregnancy test within 7 days before Day 1 dose of study medication, if female participant is of childbearing potential.
- •Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.
排除标准
- •Current or anticipated use of other investigational agents while participating in this study.
- •Pregnant or breast feeding.
- •Diagnosis of squamous cell cancer of the oropharynx
- •Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
- •Prior use of statins in the past 30 days.
- •History of rhabdomyolysis
- •Active liver disease
- •Participants who currently consume substantial quantities of alcohol (Male, more than 4 drinks a day, Female, more than 2 drinks a day)
- •Concurrent use of drugs associated with myopathy
- •Hypersensitivity to atorvastatin or any component of the formulation
- •Untreated hypothyroidism
- •Inability to comply with study and follow-up procedures as judged by the Investigator
研究组 & 干预措施
Atorvastatin
Experimental
Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
干预措施: Atorvastatin (Drug)
结局指标
主要结局
Change in conformational mutant tumor protein 53 (p53)
时间窗: baseline and up to 4 weeks
Measured by immunohistochemistry (IHC) staining. Reported as overall percent difference in the level of conformation mutant p53.
次要结局
- Change in Ki-67 (protein)(baseline and up to 4 weeks)
- Change in caspase-3(baseline and up to 4 weeks)
研究者
Joaquina Baranda
Associate Professor University of Kansas Cancer Center - Medical Oncology
University of Kansas Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
4 期
A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High CholesterolHyperlipidemiasNCT00645424Pfizer's Upjohn has merged with Mylan to form Viatris Inc.155
已完成
2 期
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cellsHIV-1 InfectionNCT01351025Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections98
已完成
2 期
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)Type 1 DiabetesNCT00529191Children's Hospital of Philadelphia40
已完成
1 期
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.Effect of Atorvastatin on the Pharmacokinetics of LomitapideNCT02080455Aegerion Pharmaceuticals, Inc.32
Unknown
2 期
An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT00432354Buddhist Tzu Chi General Hospital40